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Abstract 
The development of effective therapeutics for cancer-induced bone pain (CIBP) 
remains a tremendous challenge owing to its unclear mechanisms. 
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the 
central nervous system (CNS). Emerging studies have shown that disinhibition in the 
spinal cord dorsal horn may account for the development of chronic pain. However, 
the role of GABA in the development of CIBP remains elusive. In addition, 
accumulating evidence has shown that neuroglial cells in the peripheral nervous 
system, especially astrocytes and microglial cells, played an important role in the 
maintenance of CIBP. In this study, we investigated the expression of GABA and 
Gamma-aminobutyric acid transporter-1 (GAT-1), a transporter of GABA. Our results 
demonstrate that GABA was decreased in CIBP rats as expected. However, the 
expression of glutamic acid decarboxylase (GAD) 65 was up-regulated on day 21 
after surgery, while the expression of GAD 67 remained unchanged after surgery. We 
also found that the expression of GAT-1 was up-regulated mainly in the astrocytes of 
the spinal cord. Moreover, we evaluated the analgesic effect of exogenous GABA and 
the GAT-1 inhibitor. Intrathecal administration of exogenous GABA and NO-711 (a 
GAT-1 selective inhibitor) significantly reversed CIBP-induced mechanical allodynia 
in a dose-dependent manner. These results firstly show that neuron-glia interactions, 
especially on the GABAergic pathway, contribute to the development of CIBP. In 
conclusion, exogenous GABA and GAT-1 inhibitor might be alternative therapeutic 
strategies for the treatment of CIBP.  
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Keywords: Cancer-induced bone pain; Gamma-Aminobutyric acid; Glutamic acid 
decarboxylases; GABA transporters; NO-711; Astrocyte. 
 
1. Introduction 
Cancer-induced bone pain (CIBP) is chronic pain caused by primary or distant 
metastases of non-bone tumors, notably those in the breast, prostate, and lung (Liu et 
al., 2011; Liu et al., 2018; Zhou et al., 2016). It not only brings tremendous physical 
injury, but also causes severe negative emotions which dramatically affect the quality 
of a patient’s life (Zhou et al., 2017). Currently, drug therapeutics of CIBP are 
ineffective due to the escalating doses and unwanted side effects (Edwards et al., 2018; 
Lu et al., 2015). The development of effective therapeutics for CIBP remains a target 
of ongoing studies. 
Gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the 
central nervous system (CNS), plays an important part in controlling the transmission 
of pain information (Kontinen et al., 2001; Polgár et al., 2003). GABA is synthesized 
from glutamate by the action of two glutamic acid decarboxylases GAD65 and 
GAD67 (Kami et al., 2016). GAD65, predominantly localized in the nerve terminal in 
the laminae I–II of the spinal cord, is preferentially synthesize GABA for 
neurotransmission. While GAD67, evenly spread throughout the neurons in the deep 
laminae of the spinal cord, is preferentially synthesize cytoplasmic GABA (Pinal and 
Tobin, 1998; Soghomonian and Martin, 1998; Walls et al., 2010). 
Gamma-aminobutyric acid transporters (GATs), which transport GABA in the 
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synaptic cleft, play a critical role in regulating the homeostasis of extracellular GABA 
(Yadav et al., 2015). GATs are divided into four subtypes: gamma-aminobutyric acid 
transporter-1 (GAT-1), gamma-aminobutyric acid transporter-2 (GAT-2), 
gamma-aminobutyric acid transporter-3 (GAT-3), and Betaine/GABA transporter 1 
(BGT-1). GAT-1 is the most predominant and makes up about 80% of all GATs (Li et 
al., 2011; Smith et al., 2007). Up-regulation of GABA transporters may result in faster 
removal of GABA from the synaptic cleft of GABAergic axon terminals, which may 
trigger certain CNS disorders (Ng and Ong, 2001; Sharopov et al., 2014). Moreover, 
GABA transporter inhibitors such as Tiagabine, and NO-711 (a GAT-1 selective 
inhibitor) provide analgesic effect in neuropathic pain (Kataoka et al., 2013; Masocha 
and Parvathy, 2016). These results suggest that GAT-1 may be involved in the 
transmission of pain information. 
Several studies have shown that there is apoptosis of GABAergic neuron in the spinal 
cord which could result in the reduction of GABA and its synthesizing enzyme in 
neuropathic pain model (Fu et al., 2016; Lorenzo et al., 2014; Moore et al., 2002). 
However, other studies suggest that GABAergic neurons in the spinal cord do not 
induce apoptosis (Polgar et al., 2004). The apoptosis cells were likely to be microglia, 
rather than neurons (Polgár et al., 2005). Moreover, other studies demonstrated that 
disinhibition in the spinal cord could induced by up-regulation of GAT-1, which 
resulted in the reduction of GABA in the synaptic cleft of the spinal cord (Polgár and 
Todd, 2008). In this study, we firstly demonstrated that the neuron-glia interactions, 
especially on GABAergic pathway, contributed to the development of CIBP. 
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Moreover, intrathecal administration of exogenous GABA or GAT-1 inhibitor may be 
alternative therapeutic strategies for the management of CIBP. 
 
2. Material and methods  
2.1. Animals and ethical statement 
Due to female adult rats being more susceptible to Walker 256 mammary gland 
carcinoma cells, all experiments were performed on female adult Sprague-Dawley 
rats (180-200 g), provided by Tongji Medical College, Huazhong University of 
Science and Technology (HUST), Wuhan, People’s Republic of China and kept in a 
temperature-controlled (21 ± 1) environment under a standard 12-h light/12-h dark 
cycle with abundant food and drinking water. All experimental protocols received 
approval from the Animal Care and Used Committee of Huazhong University of 
Science & Technology and were in accordance with the National Institutes of Health 
Guide for the Care (Zimmermann, 1983). All efforts were made to minimize the 
number of animals used and their suffering. Animals were divided randomly into 
different groups. The number in each group is shown in all the figure legends. 
 
2.2. Intrathecal catheters and drug administration 
For intrathecal administration of drugs, intrathecal catheter implantation was 
completed as previously described (Gwak et al., 2008). Briefly, under pentobarbital 
sodium (50 mg/kg) anesthesia, a PE-10 polyethylene tubing (I.D. 0.25 mm and O.D. 
0.5 mm) was inserted into the intrathecal space between L5 - L6 of the spinal cord. 
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Different doses of GABA (0.5 µg, 1.0 µg, Sigma; Cat No. PARUI-QE) and 
NO-711(10 µg, 50 µg, 100 µg, Sigma) were dissolved in saline, and then injected into 
the intrathecal space in a volume of 10 µl, followed by 10 µl saline for flushing. The 
control group received the same volume of saline. The doses of GABA and NO-711 
were determined based on previous reports (Eaton et al., 1999; Li et al., 2011). The 
drug administration protocols are shown in the corresponding drug administration 
schedules (Fig. 2A, Fig. 7A). 
 
2.3. Preparation of tumor cells 
Tumor cells were prepared as described previously (Hu et al., 2017a). Briefly, Walker 
256 mammary gland carcinoma cell suspension (1 ml, 4 × 107 cells/mL) was injected 
into the abdominal cavity of female rats. After 7-10 days, cells were extracted from 
the ascitic fluid of the rat and suspended in phosphate buffered saline (PBS). Cell 
suspension was adjusted to 4 × 107 cells/mL for injection using a hemocytometer.  
 
2.4. Cancer-induced bone pain model 
The CIBP model was carried out by inoculating Walker 256 mammary gland 
carcinoma cells into the right tibia based on previous studies (Chen et al., 2018; Zhou 
et al., 2018). After anesthesia with pentobarbital sodium (50 mg/kg), a minimal 
incision in the right leg was made to expose the tibia. Then, prepared carcinoma cells 
(4 × 107 cells/mL,10 µL) were injected into the intramedullary of the right tibia using 
a 10-µL Hamilton syringe. Rats in the sham group were injected 10 µL PBS solution 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
instead. The injection site was quickly sealed with bone wax while the syringe was 
removed. Then, the wound was sutured using 3-0 silk thread. 
 
2.5. Evaluation of behavioral pain 
All animals were habituated, and basal pain sensitivity was performed before surgery. 
Animals that showed obvious abnormal data were discarded. In order to observe the 
development of mechanical allodynia after tumor cell inoculation (TCI), the pain 
behavioral test was performed on day 5, 7,14, 21 after surgery. After administration of 
GABA, NO-711 or vehicle, the pain behavior test protocols were as follows: for acute 
treatment, the pain behavior test was performed on day 14 after TCI; for chronic 
treatment, the pain behavior test was continuously performed from day 14 to day 18 
once daily after TCI. The mechanical allodynia was evaluated using the hind paw 
withdrawal threshold (PWT) according to Electronic Von-Frey methods as previously 
described (Liu et al., 2017). Rats were first placed in Plexiglas boxes with a wire 
mesh floor for about 30 min. Continuous and enhancive force was applied on the hind 
paw until the paw was withdrawn. The minimum force to evoke a positive response 
was recorded as the PWT (grams). The maximum force applied was 50 g in order to 
prevent any tissue damage. The test was performed three times with 5 min intervals 
and the average of three measurements was considered as the PWT (grams). All of the 
behavioral tests were performed by an investigator who was blind to the experimental 
design. 
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2.6. Immunofluorescence 
Rats were deeply anesthetized with pentobarbital sodium (50 mg/kg) and 
intracardially perfused with 0.1M PBS followed by 4% paraformaldehyde in 0.1M 
PBS (Hu et al., 2017b). L3-L5 spinal segments of rats were dissected and post-fixed 
in 4% paraformaldehyde overnight, and subsequently transferred to 30% sucrose 
solution until the tissues sank to the bottom at 4 . The spinal cord was sectioned 20 
µm thick and processed in accordance with standard immunofluorescence protocols. 
After washing in 0.1M PBS, the sections were blocked with 5% goat serum for 1 h at 
37, and then incubated overnight at 4  with the following primary antibodies: 
mouse anti-GAD65 (1:100; Abcam; ab26113; Cat No. GR3184556-1), mouse 
anti-GAD67 (1:100; Abcam; ab26116; Cat No. GR3188743-1), rabbit anti-GABA 
(1:100; Sigma; A2052; Cat No. 047M4852V), rabbit anti-NEUN (1:500; Abcam; 
ab177487; Cat No. GR249899-54), rabbit anti-GAT-1 (1:100; Abcam; ab426; Cat No. 
GR3202352-3), mouse anti-glial fibrillary acidic protein (GFAP) (1:500; Cell 
Signaling Technology, CST; #34001S; Lot 6), goat anti-ionized calcium 
bindingadaptor molecule-1 (Iba-1) (1:200; Abcam; ab5076; Cat No.GR256200-1). 
After washing 30 min in PBS, the sections were incubated for 2 h with the 
corresponding Alexa Fluor 488-conjugated secondary antibodies (1:100; Protomer) or 
Cy3-conjugated secondary antibodies (1:100; Protomer) then washed in PBS three 
times, followed by 4', 6-diamidino-2-phenylindole (DAPI) (Beyotime Biotechnology) 
and incubated for 15 min. Sections were cover slipped with 50% glycerol. Fluorescent 
images were captured using a fluorescence microscope (DM2500; Leica) and then 
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measured by image-pro plus software. 
 
2.7. Western blot  
Under deep anaesthesia with pentobarbital sodium (50 mg/kg), the L3-L5 spinal cord 
was immediately removed and homogenized in ice-cold radio-immunoprecipitation 
assay (RIPA) lysis buffer containing protease inhibitor cocktail (Guo et al., 2017). The 
protein concentration of supernatants was measured using the Bradford method. 40 µg 
proteins from each group were separated by 10% sodium dodecyl sulfate 
polyacrylamide gel and then transferred to polyvinylidene fluoride membranes 
(IPVH00010; EMD Millipore). After incubation in a blocking solution of 5% 
skimmed milk in Tris-buffered saline and 0.1% Tween 20 for 2 h at room temperature, 
the membrane was incubated overnight at 4  with anti–glutamic acid 
decarboxylase-GAD65 (1:1000; Abcam; ab26113; Cat No. GR3184556-1) or 
-GAD67 antibody (1:1000; Abcam; ab26116; Cat No. GR3188743-1), anti-GAT-1 
(1:1000; Abcam; ab426; Cat No. GR3202352-3), anti-GFAP (1:5000; Cell Signaling 
Technology, CST; #34001S; Lot 6), polyclone anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) antibody (1:2000; Promoter; Cat No. 60004-1-Ig), followed 
by corresponding incubation with horseradish peroxidase linked to secondary 
antibodies for 90 min at 37 . For visualization, Super-Lumia ECL Plus HRP 
Substrate Kit (K22030; Abbkine) was used and then detected using a computerized 
image analysis system (ChemiDoc XRS1, Bio-Rad, Hercules,CA). Intensity of each 
band was normalized to the internal control (GAPDH) and measured using the image 
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lab software (Bio-Rad). 
 
2.8. Statistical analysis 
All statistical analyses are presented with mean ± S.E.M. and performed using Prism 
6 (GraphPad Software). The behavioral responses to mechanical stimuli were tested 
using two-way analysis of variance with repeated measures followed by the 
Bonferroni test. Western blot data was analyzed using one-way analysis of variance 
with repeated measures followed by the Bonferroni test. P < 0.05 was considered as 
significant. 
 
3. Results 
3.1. Mechanical allodynia induced by tumor cell inoculation in female rats. 
PWTs were measured at baseline prior to surgery and on day 5, 7, 14, 21 after surgery 
in order to observe the development of mechanical allodynia in each group. Prior to 
TCI, the average mechanical threshold was 23.34 ± 0.74 g (ipsilateral) in the CIBP 
group, which showed no significant differences compared with other groups at 
baseline. The ipsilateral PWTs were significantly decreased from day 5 (ipsilateral 
16.44 ± 1.33 g) to the last observation day 21 (ipsilateral 10.25 ± 0.35 g) after TCI 
compared with the naïve or the sham group (Fig. 1A). 
 
3.2. Changes of spinal GABA in CIBP rats. 
In order to clarify the changes of GABA in the spinal cord, sections of the spinal cord 
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in each group were analyzed using immunofluorescence staining. GABA+  
immunoreactivities were mainly presented in the superficial dorsal horn of the spinal 
cord. GABA+ immunoreactivities in the spinal cord of CIBP rats were obviously 
weaker than the naïve and sham groups (Fig. 2A-E). In the images that emerged, a 
number of rounded GABA+ cells were co-expressed with NeuN (a neuron marker) 
and some were expressed in the neuropils surrounding NeuN which are consistent 
with previous reports (Fig. 2K-T).  
 
3.3. Expression of spinal GABA synthesizing enzymes GAD65 and GAD67 in 
CIBP rats. 
To further evaluate the signaling of GABA in the spinal cord and to the occurrence of 
CIBP, we performed western blot and immunofluorescence staining to evaluate 
GABA synthesis, including GABA synthesizing enzymes GAD65 and GAD67. For 
western blot, the protein levels of GAD65 on day 21 of the CIBP group were 
significantly increased compared to the naïve group (Fig. 3A-B). While, no significant 
difference was observed in the protein expression of GAD67 between the CIBP group 
and the naïve group (Fig. 4A-B). The immunofluorescence data also showed that the 
expression level of GAD65 was increased in the lamina II of the ipsilateral spinal 
dorsal horn of the CIBP group on day 21 compared to the naïve group (Fig. 3C-G). 
And in the enlarged merged images, GAD65 immunoreactivities were presented as 
punctate structures in neuropils mostly in the superficial dorsal horn of the spinal cord 
(Fig. 3R-V). GAD67 immunoreactivities were detected in neuronal cell bodies and 
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co-expressed with NeuN (Fig. 4M-V). In conclusion, GAD65 was elevated in the 
ipsilateral spinal cord of the CIBP group, while, the expression level of GAD67 
showed no significant difference in each group. 
 
3.4. Attenuation of mechanical allodynia by intrathecal administration of GABA. 
To determine whether GABA in the spinal cord was responsible for the development 
of CIBP, rats were intrathecally injected exogenous GABA. The results showed that 
intrathecal administration of a single dose of GABA (intrathecal injection (i.t.) 0.5 
µg/10 µl or 1.0 µg/10 µl) significantly reversed CIBP-induced mechanical allodynia 
on day 14 after TCI both on the ipsilateral and contralateral hind limbs compared with 
before the intrathecal drug administration and the vehicle group. The behavioral tests 
were conducted at 0, 0.25, 0.5, 1.0, 2.0, 3.0 h after GABA injection. The analgesic 
effect of GABA began at 0.25 h, peaked at 1.0 h, and lasted for 2.0 h (Fig. 5B-C). 
GABA (1.0 µg/10 µl, once a day) or vehicle (10 µl, once a day) was conducted from 
day 14 to day 18 in order to observe chronic analgesic effect and behavioral tests were 
conducted 1.0 h after GABA injection from day 14 to day 18. The results showed that 
continuous administration of 5 days GABA (1.0 µg /10 µl) could significantly 
alleviate CIBP-induced mechanical allodynia rather than the vehicle (Fig. 5D). 
 
3.5. Expression and cellular localization of spinal GABA transporter GAT-1 in 
CIBP rats. 
We also evaluated the expression of spinal GABA transporter GAT-1 in order to show 
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the clearance of GABA in the synaptic cleft in each group. For western blot, the 
expression levels of GAT-1 protein on day 14 and day 21 of CIBP group were 
significantly increased when compared with the naïve group (Fig. 6A-B). Meanwhile, 
as we expected the protein expression of GFAP (an astrocyte marker) was consistent 
with GAT-1 in each group (Fig. 6C-D). We also tested the cellular localization of 
GAT-1 (green) in the lumbar dorsal horn by double immunofluorescence with NeuN 
(red) for neurons, GFAP (red) for astrocytes, and Iba-1 (red) for microglia to further 
confirm the cellular localization of GABA transporter GAT-1. As shown in Fig. 6E-P, 
GAT-1 was mostly co-expressed with GFAP, and a minority with NeuN in the 
superficial spinal cord. These results showed that GAT-1 was up-regulated on day 14 
and day 21 after TCI and expressed mostly in astrocytes, and a minority in neurons. 
 
3.6. Effect of intrathecal injection of GAT-1 inhibitor NO-711 on the development 
of CIBP-induced mechanical allodynia. 
To explore the effect of GAT-1 inhibitor NO-711 on CIBP-induced mechanical 
allodynia, we intrathecally injected a single dose of NO-711 into CIBP rats on day 14 
after TCI. Results show that NO-711 administration dramatically attenuated 
CIBP-induced mechanical allodynia on ipsilateral hindlimb in a dose-dependent 
manner compared with the vehicle group, and the efficiency of NO-711 (100 µg/10 µl, 
and 50 µg/10 µl, on day 14) began at 0.25 h, reached a peak at 0.5 h, and lasted for 3.0 
h, except for the 10 µg/10 µl NO-711 (Fig. 7B). However, there was no significant 
analgesic effect of NO-711 on the contralateral hindlimb compared with the vehicle 
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group (Fig. 7C). 
For chronic treatment, we intrathecally administered NO-711 (100 µg/10 µl, once a 
day) or vehicle (10 µl, once a day) from day 14 to day 18 and PWTs were measured 
0.5 h after injection. As shown in Fig. 7D, continuous administration of NO-711 (100 
µg/10 µl, once a day) obviously attenuated CIBP-induced mechanical allodynia 
compared with the vehicle group. 
 
3.7. Chronic administration of GAT-1 inhibitor NO-711 suppressed the 
up-regulation of GABA transporters GAT-1 and astrocytes in CIBP rats. 
To confirm whether NO-711 exerts its analgesic effect by suppressing the expression 
of GABA transporters GAT-1 and GFAP, we intrathecally injected NO-711 (100 µg/10 
µl, once a day) into CIBP rats from day 14 to day 18. Spinal cords were collected to 
examine the expression of GABA transporters GAT-1 and astrocytes using western 
blot and immunofluorescence 0.5 h after injection. The expression of GAT-1 and 
GFAP were significantly suppressed after NO-711 treatment (Fig. 8A-B). As 
illustrated in Fig. 8C-H, immunofluorescence staining also showed that the 
immunoreactivities of GAT-1 and GFAP in the superficial dorsal horn of the spinal 
cord in the CIBP + NO-711 group were weaker than the CIBP + vehicle group. These 
results confirm that chronic treatment with GAT-1 inhibitor NO-711 could suppress 
the expression of GABA transporters GAT-1 and astrocytes in CIBP rats. 
 
4. Discussion 
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Our present study showed that: 1) The expression of GABA was decreased in the 
spinal cord in CIBP rats which is consistent with previous reports and intrathecal 
administration of exogenous GABA significantly alleviated CIBP-induced mechanical 
allodynia. 2) The increase of GAD65 might serve as a compensation mechanism to 
supplement the absence of GABA in the synaptic cleft of the spinal cord, while the 
expression of GAD67 did not change. 3) The expression of GABA transporters GAT-1 
was up-regulated on day 14 and day 21 in CIBP rats. 4) Chronic treatment of GAT-1 
inhibitor NO-711 significantly suppressed the up-regulation of both GAT-1 and GFAP 
in the ipsilateral spinal cord. In conclusion, these results firstly indicate that the 
neuron-glia interactions, especially on the GABAergic pathway, contributed to 
CIBP-induced mechanical allodynia. 
Disinhibition in the spinal cord is an important factor leading to mechanical allodynia 
in rats with neuropathic pain. One mechanism proposed accounting for the 
disinhibition was loss of GABA or its synthesizing enzyme (Moore et al., 2002). All 
these changes have been considered to result from the apoptosis of GABAergic 
neurons in the spinal cord, as indicated by a reduction of GABA-immunoreactive and 
the presence of the apoptotic marker (Lorenzo et al., 2014; Scholz et al., 2005). 
However, other studies using stereological count opposed these findings by 
suggesting that there was no significant loss of GABAergic neurons in the spinal cord 
of spared nerve injury (SNI) or chronic constriction nerve injury (CCI) model rats 
(Lee et al., 2010; Polgár et al., 2005; Polgár et al., 2003). In contrast to these studies, 
others provided evidence for an increase in GABA-immunoreactive in the spinal cord 
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(Castro-Lopes et al., 1992; Ko et al., 2018). These studies demonstrate that the 
increased GABAergic inhibitory tone measured by electrophysiology in the spinal 
cord may serve as a compensation mechanism for increased excitability in 
neuropathic pain (Kontinen et al., 2001). Thus, there are explicit discrepancies in the 
findings of these studies with regard to the complex anatomic changes related to the 
functional role of GABAergic neurons in neuropathic pain (Polgár et al., 2003). 
Therefore, it is important to investigate whether the changes of spinal GABAergic 
elements are related to the genesis and development of CIBP by comparing the 
quantities of GABA, its synthesizing enzymes GAD65 and GAD67 in the spinal cord. 
In contrast to previous studies, our results showed that the expression of GAD65 was 
elevated on day 21 after TCI. We used both western blot and immunofluorescence 
staining to analyze its expression, which could testify to the reliability of our results. 
It is difficult to illustrate the discrepancy between our results and those of previous 
studies. One possible explanation might be that the mechanism of CIBP is distinct 
from neuropathic pain. Some studies have reported that CIBP rats showed remarkable 
activation of glia cells but there was no change in the number of neurons (Schwei et 
al., 1999). Another possible reason for the change of GAD65 might be that it serves as 
a compensation mechanism to control the balance of GABA and glutamate which is 
consistent with the electrophysiologic results of Kontinen study (Kontinen et al., 
2001). 
Another possible mechanism of disinhibition was depletion of GABA in the synaptic 
cleft. GABA transporters play a vital role in the homeostasis of GABA in the synaptic 
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cleft of the spinal cord. In normal conditions, the expression of GABA is controlled 
by GABAergic neurons and astrocytes GABA transporters through the mechanism of 
glutamate-GABA cycle (Gwak and Hulsebosch, 2011). GABA transporters control the 
homeostasis between excitatory and inhibitory information by clearing GABA 
released from presynaptic terminals in the spinal cord (Yadav et al., 2015). In recent 
years, accumulating evidence has shown that neuroglial cells in the peripheral nervous 
system, especially astrocytes and microglial cells, played an important role in the 
genesis and maintenance of CIBP (Guo et al., 2016; Zhang et al., 2005). It has also 
been confirmed that the expression of GAT-1 was elevated in the paclitaxel or CCI 
model (Daemen et al., 2008; Gosselin et al., 2010). However, the neuron-glia 
interactions on the GABAergic pathway in CIBP rats were not exactly shown. In our 
study, we found that the up-regulation of astrocytes and GABA transporters GAT-1 in 
the ipsilateral spinal cord contributed to the genesis and development of CIBP. In 
addition, intrathecal administration of GAT-1 inhibitor NO-711 significantly 
attenuated CIBP-induced mechanical allodynia. 
 
5. Conclusion 
In conclusion, the present study suggests that loss of inhibition in the spinal dorsal 
horn contribute to the development of CIBP. Our data showed that intrathecal delivery 
of GABA or pharmacologically inhibition of GAT-1 could attenuate CIBP-induced 
mechanical allodynia. Therefore, spinal GABA and GAT-1 might be a potential 
therapeutic target for cancer pain. 
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Figure legends 
Fig. 1.: Tumor cell inoculation induced mechanical allodynia in female rats. (A) 
CIBP ipsilateral PWTs were significantly decreased from day 5 after TCI to the last 
observation on day 21 (*** P < 0.001 compared with the naïve group, ### P < 0.001 
compared with the sham group, N = 10 in each group). While, the naïve and sham 
groups showed no obvious change during 21 days. 
 
Fig. 2.: Changes of GABA in the ipsilateral spinal cord after TCI. (A-J) 
Immunoreactivities of GABA (green) and NeuN (red) in the ipsilateral spinal cord in 
each group. The fluorescence intensity of GABA (green) in the spinal cord of CIBP 
rats was weaker than the naïve and sham groups (N = 4 in each group). (K-T) As we 
detected in the merged images, some GABA (green) immunoreactivities were 
co-expressed with NeuN (red) and some were expressed in the neuropils surrounding 
NeuN (red) (N = 4 in each group). 
 
Fig. 3.: Expression of spinal GABA synthesizing enzymes GAD65 in CIBP rats. 
(A-B) Western blot analysis showed that GAD65 protein expression in the dorsal horn 
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was significantly up-regulated on day 21 post TCI of CIBP group (*** P < 0.001 
compared with the naïve group, N = 6 in each group). (C-G) Immunofluorescence 
staining showed that the increased GAD65 (green) was mainly expressed in the 
lamina II of lumbar dorsal horn of ipsilateral spinal cord (N = 4 in each group). (R-V) 
The enlarged merge images showed that GAD65 (green) immunoreactivities were 
expressed as punctate structures in neuropils (N = 4 in each group).  
 
Fig. 4.: Expression of spinal GABA synthesizing enzymes GAD67 in CIBP rats. 
(A-B) Western blot analysis showed that GAD67 protein expression in the spinal 
dorsal horn had no difference in each group (P > 0.05 compared with the naïve group, 
N = 6 in each group). (C-G) Immunofluorescence staining showed that GAD67 (green) 
was spread evenly throughout GABAergic neurons in the deep laminae of the spinal 
cord (N = 4 in each group). (R-V) The enlarged merge images showed that GAD67 
(green) immunoreactivities were expressed in neuronal cell bodies and co-expressed 
with NeuN (a neuron marker) (N = 4 in each group). 
 
Fig. 5.: Intrathecal administration of GABA alleviated CIBP-induced mechanical 
allodynia. (A) Scheme of GABA administration and behavioral assessment in CIBP 
rats. (B-C) A single dose of GABA (i.t. 0.5 µg/10 µl and 1.0 µg/10 µl on day 14) 
significantly alleviated CIBP-induced mechanical allodynia both on the ipsilateral and 
contralateral hindlimbs (* P < 0.05, ** P < 0.01, *** P < 0.001 compared with the 
CIBP + vehicle group. # P < 0.05, ## P < 0.01, ### P < 0.001 compared with before 
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intrathecal drug administration, N = 6 in each group). (D) The development of 
CIBP-induced mechanical allodynia was attenuated by the continuous administration 
of 5 days GABA (i.t. 1.0 µg/10 µl, once a day) (*** P < 0.001 compared with the 
CIBP + vehicle group. # P < 0.05, ## P < 0.01, ### P < 0.001 compared with the 
naïve group, N = 6 in each group). 
 
Fig. 6.: Expression and cellular localization of GAT-1 in the dorsal horn of spinal 
cord in CIBP rats. (A-B) Western blot analysis showed that the time course of 
GAT-1 protein expression in the dorsal horn on day 7, day 14 and day 21 post TCI (* 
P < 0.05, ** P < 0.01 compared with the naïve group, N = 6 in each group). (C-D) As 
we respect that the expression of GFAP (an astrocyte marker) is consistent with 
GAT-1 (** P < 0.01, *** P < 0.001 compared with the naïve group, N = 6 in each 
group). (E-P) Representative photomicrographs of GAT-1 (green) double fluorescence 
labeling with NeuN (red) for neurons, GFAP (red) for astrocytes, and Iba-1 (red) for 
microglia in the ipsilateral spinal cord on day 14 after TCI. The results showed that 
GAT-1 was co-expressed mostly with GFAP (yellow) and minority with NeuN 
(yellow) (N = 4 in each group).  
 
Fig. 7.: Intrathecal administration of GAT-1 inhibitor 
NO-711alleviatedCIBP-induced mechanical allodynia. (A) Scheme of NO-711 
administration and behavioral assessment in CIBP rats. (B-C) A single dose of 
NO-711 (i.t. 100 µg/10 µl and 50 µg/10 µl, but not 10 µg/10 µl, on day 14) 
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significantly reversed the CIBP-induced mechanical allodynia on ipsilateral hindlimb. 
However, there was no significant analgesic effect of NO-711 on the contralateral 
hindlimb. The result showed that only a single dose of 100 µg NO-711 reversed the 
CIBP-induced mechanical allodynia on contralateral hindlimb at 0.5 h after NO-711 
administration (* P < 0.05, *** P < 0.001 compared with the CIBP + vehicle group, N 
= 4 in each group). (D) For chronic treatment, NO-711 (i.t. 100 µg/10 µl, once a day) 
or vehicle was injected for 5 days (from day 14 to day 18 after TCI) and PWTs were 
measured 0.5 h after injection. The ipsilateral mechanical allodynia was obviously 
reversed by NO-711 (100 µg/10 µl) (* P < 0.05, ** P < 0.01, *** P < 0.001 compared 
with the CIBP + vehicle group. ## P < 0.01, ### P < 0.001 compared with the naïve 
group, N = 4 in each group). 
 
Fig. 8.: Repeated intrathecal administration of NO-711 (100 µg/10 µl) reversed 
CIBP-induced up-regulation of GAT-1 and astrocytes in the spinal cord. 
(A) Western blot data showed that the protein expression of GAT-1 was 
down-regulated in the CIBP + NO-711 group (** P < 0.01 compared with the CIBP + 
vehicle group, N = 4 in each group). (B) The expression of GFAP was also suppressed 
in the CIBP + NO-711 group (* P < 0.05 compared with the CIBP + vehicle group, N 
= 4 in each group). (C-H) Immunofluorescence staining also demonstrated that 
NO-711 (100 µg/10 µl) reversed the increase of GABA transporters GAT-1and 
astrocytes in the spinal cord in CIBP rats. 
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